Ignite Creation Date:
2025-12-25 @ 4:32 AM
Ignite Modification Date:
2025-12-26 @ 3:34 AM
Study NCT ID:
NCT06063018
Status:
RECRUITING
Last Update Posted:
2023-10-02
First Post:
2023-09-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Sponsor:
Peking Union Medical College Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08-16
Start Date Type:
ACTUAL
Primary Completion Date:
2025-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-08
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-11
First Submit QC Date:
None
Study First Post Date:
2023-10-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-25
Last Update Post Date:
2023-10-02
Last Update Post Date Type:
ACTUAL